The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal milieu deriving from these parameters is associated with alterations in bone metabolism, lipoprotein concentration and function, and/or the severity and complications of obesity. It will be also investigated if this hormonal milieu is a predictive factor for cardiovascular disease in obese patients. Eligible subjects are male patients (age 18-80 years) with severe obesity and no other known causes of hypercortisolism or hypogonadism. Questionnaires for the evaluation of mood and symptoms will be collected upon enrollment, patient's anamnestic and clinical data relating to disease complications, BMI, previous blood tests, cortisol suppression with dexamethasone 1 mg will be collected, and blood sample will be sent to and analyzed at a centralized laboratory for the study of Steroid hormones, bone metabolism, lipoprotein function, genetics and receptor analysis.
Study Type
OBSERVATIONAL
Enrollment
180
Istituto Auxlogico Italiano, Hospital San Giuseppe, Piancavallo
Oggebbio, Verbania, Italy
RECRUITINGAssociation of androgen milieu with the severity of obesity
Evaluate the association of hypogonadism and/or androgen receptor polymorphisms that reduce sensitivity to androgens with: patients' BMI; comorbidities of obesity, and bone metabolism
Time frame: 2024
Association of cortisol milieu with the severity of obesity
Evaluate the association of hypercortisolism and/or glucocorticoid receptor polymorphisms that increase sensitivity to cortisol with: patients' BMI; comorbidities of obesity, and bone metabolism
Time frame: 2024
Algorithm fo CV risk in obesity
Use of artificial intelligence methods to hypothesize an algorithm including steroid milieu that can identify obese patients at greater cardiovascular risk
Time frame: 2024
Prevalence of hypogonadism in morbid obesity
To evaluate the prevalence of hypogonadism in patients with severe obesity using EMAS criteria
Time frame: 2024
Prevalence of patients with morbid obesity unresponsive to overnight suppression test
To evaluate the prevalence of patients with severe obesity positive to Nugent testing
Time frame: 2024
Enrichment in rare HH variants in obese patients with central hypogonadism
Compare the enrichment in rare variants for HH-associated genes in obese patients with hypogonadotropic hypogonadism, compared to the general population
Time frame: 2025
Enrichment in rare variants associated with hypercortisolism in obese patients unresponsive to Nugent testing
Compare the enrichment in rare variants in genes associated with hypercortisolism in obese patients unresponsive to Nugent testing, compared to the general population
Time frame: 2025
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.